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Abstract 
Poly-lactic-co-glycolic acid can form nanoparticles which can be applied in nanomedicine as 
delivery vehicle for therapeutic agents. Here the aim is to reduce negative side-effects and to 
obtain higher local concentrations at the site of action. This work is about determining the 
binding-capacity of PLGA nanoparticles to several substances, applying a small set of model 
proteins. Our aim was to find out, whether PLGA nanoparticles can transport drugs in order to 
make drug targeting in medicine easier. This would show us a new section of medicine with new 
ways of therapy methods.  
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Introduction 
Nanotechnology has become more and more important in many sectors from industry to 
medicine. Here, advances have been made in cancer therapy and diagnostics. Even a hybrid 
technology has been developed employing so-called theranostics, which can be used for 
diagnosis and therapy at the same time. Drug targeting is performed when specific markers guide 
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the therapeutic vehicle directly to its action site in the human body. By such means, a much 
higher local dose can be reached and the side reactions are much less. Healthy tissue remains 
unaffected by this type of highly effective therapy. 
Poly-lactic-co-glycolic acid (PLGA) are polymers consisting of two different monomers, lactic acid 
and glycolic acid. As they are organic substances, they can be degraded by the human metabolism 
and are therefore biocompatible. PLGA-NPs can be used in nanomedicine for the administration 
of drugs, in particular for treatments based on biologics. These can be antibody treatments, such 
as immunotherapy in cancer. In my internship at the University of Salzburg we were using Vitamin 
E TPGS (0.3% & 0.9 %) and PVA (Polyvinyl Alcohol) (0.3%), as emulgators to optimize the process of 
PLGA-nanoparticle formation. Emulgators act to mix two substances, which are per se hard to 
mix. Without emulgators two phases can be observed. Emulgators form very tiny droplets of one 
liquid substance in another one. The emulsion effects of the different approaches which were 
conducted to optimize the PLGA-NPs were monitors by nanoparticle tracking analysis (NTA). Here 
the aim was that rather small agglomerates were produced. As NTA uses light scattering one uses 
the term “monodispers” for a suspension which rather contains only one size of agglomerates. 
Different means, such as vortexing speed and ultrasonication, were used to find the best 
conditions yielding a PLGA-NP suspension with a low degree of polydispersity. 
 
Synthesis of biodegradable PLGA nanoparticles by emulsion solvent evaporation 
 
1) mix 100 mg PLGA with 1ml Ethyl Acetate 
(test tube I) 
(on Vortexer)  
2) mix 0.3 g Vitamin E TPGS with 
 100 ml of distilled water (dH2O) 
(on magnetic stirrer until fully dissolved; use stir bar)  
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3) after it fully dissolves separate 45 ml of 
the liquid into a beaker and place it on the 
magnetic stirrer (360 rpm) 
4)  transfer 2 ml of the Vitamin E TPGS 
dissolved in dH2O into a test tube (test 
tube II) 
5) afterwards vortex test tube II and 
transfer the contents in test tube I to test tube II with a Pasteur pipette 
6) use a probe sonicator to sonicate the final liquid of PLGA + Vitamin E 
TPGS. This results in a colour change from light white to milky white. 
7) after that fill the fluid into Eppendorf tubes (2 ml) and put them into 
Finally add the liquid from the Sonicator to the 45 ml of Vitamin E TPGS  
(leave on magnetic stirrer for 3 hours) 
8) ultracentrifuge (15 min; -6˚ C; highest speed 17000 g, two times) 
9) after each centrifugation step 
collect the supernatant, without taking 
the particles which settled on the 
ground, with a pipette into a Greiner 
(50 ml). Refill Eppendorf tubes with 
water and use the ultracentrifuge for a second time with the same settings 
10) fill particles mixed with water into a Greiner- Now there’s a possibility to 
check the size of the particles by making an NTA-test 
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Vortexing  Vitamin E TPGS  Centrifuge          Magnet stirrer 
 
Size determination of PLGA particles 
Four different solutions were investigated by NTA: 
• PLGA nanoparticle + 0.3% w/v PVA  (speed: 360 rpm, time: 4 h, dilution: 1:100) 
➢ larger size (184.9 nm)  
➢ very polydispers  
➢ 7.14e+008 +/- 2.95e+008 particle/ml 
• PLGA nanoparticle + 0.3% w/v Vitamin E TPGS (speed: 360 rpm, time: 4 h, dilution: 1:100) 
➢ size ~ 275.9 nm 
➢ polydispers – but less than with PVA  
➢  2.00e+009 +/- 7.98e+007 particle/ml 
• PLGA nanoparticle + 0.9% w/v Vitamin E TPGS (speed: 360 rpm, time: 4 h, dilution: 1:100) 
➢ size ~216.9 nm 
➢ most monodispers from all examples 
➢ 2.54e+009 +/- 6.19e+007 particle/ml 
• PLGA nanoparticle + 0.9% w/v Vitamin E TPGS (speed: 1100 rpm, time: 4 h, dilution: 1:100) 
➢ size ~ 214.4 nm 
➢ low polydispersity 
➢ 2.47e+009 +/- 6.53e+007 particle/ml 
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In summary, the biggest difference was observed between 0.3% w/v PVA and 0.3% w/v Vitamin 
E TPGS solutions. The difference between 0.3 and 0.9% w/v Vitamin E TPGS at 360 rpm 
centrifugation speed was not as big as with PVA. Different centrifugation speeds 360, 1100 rpm 
do not differ with Vitamine E solutions. We saw that PVA and Vitamine E have an influence on 
dispersity and size of the resulting NPs, concentration has an influence too, as well as the 
centrifugation speed. The size of the PLGA-NPs was not reduced by ultrasonication, which was 
surprising. 
 
Gel electrophoresis of PLGA-bound protein 
Some of the proteins mix with the nanoparticles and bind to them. In order to find out the real 
amount of proteins which bound to the particles, SDS PAGE is needed. The process is parted into 
two sections: the first part is separating the proteins by their size in the SDS- Gel and afterwards, 
coloring the Gel with Coomassie R250 to determine the amount of the proteins bound with the 
particles.  The second part is quantifying the unbound proteins in the supernatant by using 
Bradford Assay. Having finished both parts, the quantity of the proteins bound to PLGA-
nanoparticles can be determined with several devices.   
Preparation of samples for SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
1) The nanoparticles are filled into Eppendorf Tubes (100 μg/ml) and mixed with proteins 
(20,40 μg/ml), lysozyme (LYZ) or bovine serum albumin (BSA). In addition to that, the 
“eppis” must be pinned on a Tube Rotator overnight (20-24 h). During this time. The 
proteins will be ideally bound to the particles and build a Bio Corona around themselves.  
2) Now the liquids need to be centrifuged (5000 g, 5 h, 4˚C) so that the bound particles settle 
down. Afterwards the supernatant including the unbound proteins is removed and filled 
into other eppis (for each LYZ & BSA 3 eppis, 10/20/40 μl). They will be needed in the 
second part of the experiment.  
3) Preparing our standardized samples in order to compare the bound particles to them is 
the next step. If we know the concentration of our standardized samples, the amount of 
our bound proteins can be guessed. For our standardized samples we used the following 
concentrations: 
- 40 μg/ml   - 10 μg/ml    
- 20 μg/ml   - 5 μg/ml  
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4) For our samples we need to mix each Lysozyme and BSA eppi with 12μl water and 4 μl 
denaturing buffer, heat them to 95˚C for 10 minutes and centrifuge shortly. The reducing 
agent includes: 
- SDS (breaks complex protein structures into a linear chain of amino acids)  
- -mercaptoethanol (breaks the strong di-sulfide bonds in the proteins) 
- Tris Chloride 
- Glycerol (makes proteins foreseeable while putting them into the stacking gel) 
- Water 
- Bromphenol blue (makes proteins foreseeable while putting them into the stacking 
gel)   
5) In order to find out the amount of the unbound proteins, standardized samples, in the 
same concentration as used before, are necessary. To get these, 40 μl sample is mixed 
with 160 μl Bradford reagent. Thus a dilution of 1:4 is achieved. As soon as the samples 
are mixed with Bradford reagent, the colour of the sample changes from reddish brown 
to blue in the presence of protein. The intensity of the colour determines the amount of 
the proteins and is measured as absorbance with a Plate Reader. Below, the reducing 
agent for breaking the disulfide bridges and a microtiter plate used for photometric 
measurements are shown. 
 
 
 
 
 
Conducting SDS-PAGE  
1) Two gels, a stacking gel and a separating gel, are used to determine the quantity of the 
bound particles. The separating gel, which must be produced firstly as it has to be placed 
under the stacking gel separates the bound molecules by their size. This includes: 
- 7,5 ml H2O  
- 7,5 ml loading buffer 
- 15 ml acrylamide 
- 15 μl TEMED  
- 90 μl Aps 
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2) Next step is producing the stacking gel. This is prepared with the following components: 
- 5,2 ml H2O 
- 2,2 ml upper buffer 
- 1,4 ml acrylamide 
- 14 μl TEMED  
- 100 μl APS  
In order to form the gel wells a comb 
is needed, which must be placed in 
the device after filling in the liquid 
stacking gel above the separating gel 
as depicted at the right side.  
 
3) Afterwards, the two gels prepared are placed oppositely so that the running buffer can 
be filled between. Having done that, the device must be connected to power cables and 
therefore to the voltage source as well (0.06 A for 45 min) so that one end has a positive 
charge and the other end a negative charge. In this electric field the proteins will be 
separated by their size, generally, using an electric field to influence an object’s motion is 
called electrophoresis. The more concentrated the gel is, the slower proteins will traverse 
through it.  Small proteins travel more quickly and therefore migrate further through the 
gel. 
After some time, the proteins travel down based on their size. The amount of proteins 
present can be determined from the bands developed. These bands can be compared to 
the standardized samples and one can guess the amount.  
4) Having removed the gels from the device, they should be put in Coomassie Blue for 30 
min so that the proteins get an intensive color and can be seen better. After that, the gels 
were kept in destaining buffer for some time to reduce the background staining. 
5) To determine the exact amount, an image is taken using a digital camera. The image is 
further evaluated using a specific software (ImageLab). Below the gel after running with 
blue marker depicting the gel slots is shown on the left. At the right side the staining 
procedure is shown. 
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Below the two SDS-PAGE gels of BSA (left side) and lysozyme (right side) are shown. The first lane 
of each gel shows the protein size marker verifying the molecular weight of the proteins. The 
subsequent four bands indicate different concentrations of protein standards allowing 
quantification by comparison. In the last two lanes show the two respective nanoparticle-bound 
proteins, BSA and lysozyme. 
 
 
 
 
 
 
 
 
 
Conclusions 
Using this procedure we were able to quantify the amount of nanoparticle-bound proteins. 
However, the binding efficiency was very low. It was thus concluded that further, alternative 
procedures, like e.g. encapsulation of protein into the PLGA nanoparticles, could be adopted to 
improve protein loading. 
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